Studio di Fase 2 randomizzato in aperto, che valuta Abemaciclib in combinazione con Irinotecan e Temozolomide, in partecipanti con sarcoma di Ewing recidivato o refrattario

Title

Code

J1S-MC-JP04

Type

Sperimentale

Start Year

2023

Status

In Corso

Principal Investigator

051-6366101

emanuela.palmerini@ior.it

Palmerini Emanuela, MD

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Description

Lo studio è promosso da Eli Lilly and Company.

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio clinico prot. J1S-MC-JP04

Tuesday 3 January 2023, 16:45

19018.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Studio di Fase 2 randomizzato in aperto, che valuta Abemaciclib in combinazione con Irinotecan e Temozolomide, in partecipanti con sarcoma di Ewing recidivato o refrattario

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Studio di Fase 2 randomizzato in aperto, che valuta Abemaciclib in combinazione con Irinotecan e Temozolomide, in partecipanti con sarcoma di Ewing recidivato o refrattario

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in